Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daming Zhu

Showing results (101-110 of 111) with videos related to

Pageof 12
Sort By:
Nature Materials|February 26, 2020
Bandgap tuning of two-dimensional materials by sphere diameter engineeringMengqi Zeng, Jinxin Liu, Lu Zhou, et al.
Nature Communications|July 7, 2025
Enhanced specific energy in fast-charging lithium-ion batteries negative electrodes via Ti-O covalency-mediated low potentialJun Huang, Qirui Yang, Anyi Hu, et al.
NPJ Vaccines|August 15, 2017
A malaria vaccine protects <i>Aotus</i> monkeys against virulent <i>Plasmodium falciparum</i> infectionPrakash Srinivasan, G Christian Baldeviano, Kazutoyo Miura, et al.
Plos One|July 10, 2008
Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51Yimin Wu, Ruth D Ellis, Donna Shaffer, et al.
The Journal of Clinical Investigation|February 9, 2021
Pfs230 yields higher malaria transmission-blocking vaccine activity than Pfs25 in humans but not miceSara A Healy, Charles Anderson, Bruce J Swihart, et al.
Plos One|October 18, 2016
Safety and Immunogenicity of Pfs25-EPA/Alhydrogel®, a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria Naïve AdultsKawsar R Talaat, Ruth D Ellis, Janet Hurd, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 27, 2014
Combining viral vectored and protein-in-adjuvant vaccines against the blood-stage malaria antigen AMA1: report on a phase 1a clinical trialSusanne H Hodgson, Prateek Choudhary, Sean C Elias, et al.
The Lancet. Infectious Diseases|August 1, 2018
Safety and immunogenicity of Pfs25H-EPA/Alhydrogel, a transmission-blocking vaccine against Plasmodium falciparum: a randomised, double-blind, comparator-controlled, dose-escalation study in healthy Malian adultsIssaka Sagara, Sara A Healy, Mahamadoun H Assadou, et al.
NEJM Evidence|June 24, 2025
A Vaccine to Block <i>Plasmodium falciparum</i> TransmissionSara A Healy, Issaka Sagara, Mahamadoun H Assadou, et al.
Plos One|July 30, 2011
Impact on malaria parasite multiplication rates in infected volunteers of the protein-in-adjuvant vaccine AMA1-C1/Alhydrogel+CPG 7909Christopher J A Duncan, Susanne H Sheehy, Katie J Ewer, et al.
Pageof 12

Showing results (101-110 of 111) with videos related to

Sort By:
Pageof 12
Nature Materials|February 26, 2020
Bandgap tuning of two-dimensional materials by sphere diameter engineeringMengqi Zeng, Jinxin Liu, Lu Zhou, et al.
Nature Communications|July 7, 2025
Enhanced specific energy in fast-charging lithium-ion batteries negative electrodes via Ti-O covalency-mediated low potentialJun Huang, Qirui Yang, Anyi Hu, et al.
NPJ Vaccines|August 15, 2017
A malaria vaccine protects <i>Aotus</i> monkeys against virulent <i>Plasmodium falciparum</i> infectionPrakash Srinivasan, G Christian Baldeviano, Kazutoyo Miura, et al.
Plos One|July 10, 2008
Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51Yimin Wu, Ruth D Ellis, Donna Shaffer, et al.
The Journal of Clinical Investigation|February 9, 2021
Pfs230 yields higher malaria transmission-blocking vaccine activity than Pfs25 in humans but not miceSara A Healy, Charles Anderson, Bruce J Swihart, et al.
Plos One|October 18, 2016
Safety and Immunogenicity of Pfs25-EPA/Alhydrogel®, a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria Naïve AdultsKawsar R Talaat, Ruth D Ellis, Janet Hurd, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 27, 2014
Combining viral vectored and protein-in-adjuvant vaccines against the blood-stage malaria antigen AMA1: report on a phase 1a clinical trialSusanne H Hodgson, Prateek Choudhary, Sean C Elias, et al.
The Lancet. Infectious Diseases|August 1, 2018
Safety and immunogenicity of Pfs25H-EPA/Alhydrogel, a transmission-blocking vaccine against Plasmodium falciparum: a randomised, double-blind, comparator-controlled, dose-escalation study in healthy Malian adultsIssaka Sagara, Sara A Healy, Mahamadoun H Assadou, et al.
NEJM Evidence|June 24, 2025
A Vaccine to Block <i>Plasmodium falciparum</i> TransmissionSara A Healy, Issaka Sagara, Mahamadoun H Assadou, et al.
Plos One|July 30, 2011
Impact on malaria parasite multiplication rates in infected volunteers of the protein-in-adjuvant vaccine AMA1-C1/Alhydrogel+CPG 7909Christopher J A Duncan, Susanne H Sheehy, Katie J Ewer, et al.
Pageof 12